<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02171637</url>
  </required_header>
  <id_info>
    <org_study_id>1200.1</org_study_id>
    <nct_id>NCT02171637</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Open Label Dose Escalation Study of Once-daily Oral Treatment With BIBW 2992 for 14 Days in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Evaluation of maximum Tolerated Dose (MTD), safety, pharmacokinetics, efficacy of BIBW 2992,
      pharmacodynamic modulation of biomarkers, correlation of Epidermal Growth Factor Receptor
      (EGFR) and Human EGF-like Receptor number 2 (HER2) immunohistochemical status with objective
      tumour responses
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>up to 28 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and intensity of Adverse Events (AE) according to Common Terminology Criteria for Adverse Events (CTCAE) associated with increasing doses of BIBW 2992</measure>
    <time_frame>up to 28 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) for different time points</measure>
    <time_frame>up to 384 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose plasma concentration (Cpre) for different time points</measure>
    <time_frame>Day 8 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum measured plasma concentration (Cmin) for different time points</measure>
    <time_frame>up to 384 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum measured plasma concentration (Cmax) for different time points</measure>
    <time_frame>up to 384 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the minimum plasma concentration (tmin) for different time points</measure>
    <time_frame>up to 384 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the maximum plasma concentration (tmax) for different time points</measure>
    <time_frame>up to 384 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) for different time points</measure>
    <time_frame>up to 384 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time after oral administration (MRTpo) for different time points</measure>
    <time_frame>up to 384 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F) for different time points</measure>
    <time_frame>up to 384 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal phase (Vz/F) for different time points</measure>
    <time_frame>up to 384 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (RA)</measure>
    <time_frame>up to 384 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modulation of biomarker (EGFR, p-EGFR, p-MAPK (mitogen-activated protein kinase), p-Akt, Ki-67, p-27KIP1) in skin biopsies prior to administration of BIBW 2992 and at the end of the first treatment period</measure>
    <time_frame>Baseline and day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modulation of biomarker (EGFR, p-EGFR, HER2, p-MAPK, p-Akt, Ki-67, p-27KIP1) in tumor biopsies prior to administration of BIBW 2992 and at the end of the first treatment period in 6 or more patients treated at the MTD</measure>
    <time_frame>Baseline and day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor responses</measure>
    <time_frame>every 8 weeks up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of EGFR, HER2, estrogen receptor and progesterone receptor immunohistochemical status as based on tumor biopsies or excisions obtained prior to this trial with objective tumor responses</measure>
    <time_frame>up to 28 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>BIBW 2992</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBW 2992</intervention_name>
    <description>escalating doses</description>
    <arm_group_label>BIBW 2992</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients with confirmed diagnosis of advanced, non resectable and / or
             metastatic solid tumors, of types historically known to express EGFR and/or HER2, who
             have failed conventional treatment, or for whom no therapy of proven efficacy exists,
             or who are not amenable to established forms of treatment

          -  Age 18 years or older

          -  Life expectancy of at least three (3) months

          -  Written informed consent given that is consistent with International Conference on
             Harmonization - Good Clinical Practice (ICH-GCP) guidelines

          -  Eastern Cooperative Oncology Group (ECOG) performance score 0, 1, or 2

          -  Patients must have resolution of prior chemo-, hormone, immuno-, or
             radiotherapy-related toxicities to CTC Grade &lt; 1

          -  Patients have to be recovered from previous surgery

          -  Paraffin-embedded tumor material must be accessible for analysis of EGFR and
             HER2-status.

          -  The additional 12 patients that were to be recruited at the MTD also had to fulfill
             the following criterion: Measurable tumor deposits (RECIST: Response Evaluation
             Criteria in Solid Tumors) by one or more techniques (X-ray, CT, MRI)

        Exclusion Criteria:

          -  Active infectious disease

          -  Gastrointestinal disorders that might interfere with the absorption of the study drug
             or chronic diarrhea

          -  Serious illness or concomitant non-oncological disease considered by the investigator
             to be incompatible with the protocol

          -  Brain metastases requiring therapy as based on clinical symptoms

          -  Impaired cardiac left ventricular function with resting ejection fraction CTC Grade ≥
             1

          -  Absolute neutrophil count (ANC) less than 1500 / mm3

          -  Platelet count less than 100 000 / mm3

          -  Bilirubin greater than 1.5 mg / dl (&gt; 26 μmol / L, SI unit equivalent)

          -  Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater
             than three times the upper limit of normal (if related to liver metastases greater
             than five times the upper limit of normal)

          -  Serum creatinine greater than 1.5 mg / dl (&gt; 132 μmol / L, SI (Systeme International)
             unit equivalent)

          -  Women and men who are sexually active and unwilling to use a medically acceptable
             method of contraception

          -  Pregnancy or breast-feeding

          -  Treatment with other investigational drugs; chemotherapy, immunotherapy, radiotherapy
             or hormone therapy (excluding LHRH agonists, other hormones taken for breast cancer,
             or bisphosphonates) or participation in another clinical study within the past four
             weeks before start of therapy or concomitantly with this study

          -  Patients unable to comply with the protocol

          -  Active alcohol or drug abuse

        RETREATMENT CRITERIA

        The patient may be eligible for re-treatment after the previous course finished. The
        patient will not be eligible if the following criteria are met.

          -  Patients with clinical signs of disease progression or if an X-ray, CT or MRI was done
             and the test showed progressive disease

          -  Cardiac left ventricular function CTC Grade ≥ 2 at any time during the previous course

          -  Patients fulfilling any of the Exclusion Criteria as mentioned under exclusion
             criteria on Day 29 of the previous course

          -  Patients not recovered from any dose-limiting toxicity (DLT) 14 days after the last
             administration of BIBW 2992 in the previous course. Recovery is defined as a return to
             baseline level or CTC Grade 1, whichever is higher
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

